Choosing an Active Pharmaceutical Ingredient Supplier

Choose an active pharmaceutical ingredient supplier in five checks: seller role, technical fit, quality evidence, US regulatory support, and supply continuity. Compare quotes only after each candidate identifies the exact manufacturing site, API specification, and evidence package for your program.

A low price cannot solve a missing Letter of Authorization, an untraceable batch, or a process change that disrupts your filing. Use the scorecard below to move procurement, quality, regulatory, and formulation teams through the same decision.

Score Each Supplier Before Comparing Quotes

Use this scorecard after a supplier passes three gates: it names the original manufacturer and site, confirms the exact API and dosage-form requirements, and explains the intended US filing or import path.

Score each row as follows: 0 means the supplier provided nothing usable. 1 means the supplier made a general claim. 2 means the supplier provided relevant but incomplete material. 3 means the supplier provided current, API-specific, site-specific evidence. 4 means the supplier also commits to that evidence in the supply or quality agreement.

Calculate each result as weight × score ÷ 4. Rank only suppliers that pass every gate. A quality or regulatory failure removes a supplier from consideration, even if its total score is high.

Send every candidate this request:

Please confirm the legal selling entity, original API manufacturer, exact manufacturing site, and every storage, repackaging, and distribution location. For the proposed API, provide the current specification, analytical methods, representative impurity profile, three recent batch CoAs, stability or retest information, and applicable particle-size, polymorph, microbiological, or endotoxin data.

State the US regulatory path for this material. Where a Type II DMF applies, identify the holder, covered API and site, and LOA availability. For US import, provide the foreign establishment registration, API listing, US agent, and named importer. Confirm capacity, batch range, lead time, storage conditions, shipment plan, change-notification process, and quality-agreement responsibilities.

The scorecard turns a supplier search into a documented approval decision. It also exposes when a broker can source a material but cannot support the quality or regulatory work your program needs.

1. Identify the Manufacturer, Distributor, or Broker

The selling company’s label does not identify its actual role. Ask who operates the named manufacturing site, who takes possession of the API, and who can provide the original batch records.

A manufacturer operates the site that makes the batch. A distributor may store, ship, repack, or relabel the material. A broker or agent may arrange the sale without operating the manufacturing site.

The distinction matters because the original manufacturer controls the process, batch record, and change control. A distributor can still be useful when it provides local inventory or logistics support, but the buyer still needs visibility to the original site.

ICH Q7 requires agents, brokers, traders, distributors, repackers, and relabellers to retain traceability records. Those records include the original manufacturer’s identity and address, the manufacturer’s batch number, transport records, and authentic CoAs.

Ask these three questions first:

1. “Which site will manufacture my qualification and commercial batches?”
2. “Will your company store, repackage, relabel, or otherwise handle the API?”
3. “Can you provide the original manufacturer’s CoA and batch traceability records?”

A supplier that cannot answer all three has not passed the first gate.

2. Match the API to Your Dosage Form

The API name alone is not a complete technical requirement. Your purchase specification must match the material that your formulation, analytical methods, and regulatory file require.

Start your technical brief with the API’s exact name, salt or solvate form, pharmacopoeial grade, intended dosage form, annual demand, and target batch size. Add any critical physical properties before requesting samples.

For oral solids, assess particle-size distribution, flow, polymorph, compressibility, and dissolution behavior. For sterile or parenteral products, add microbiological and endotoxin requirements where relevant. For peptides, hormones, high-potency APIs, and temperature-sensitive materials, add handling, containment, stability, and transport requirements.

ICH Q7 says API specifications should control relevant organic impurities, inorganic impurities, and residual solvents. It also expects an impurity profile for a typical batch from a controlled production process.

Ask for the current specification and test methods, not a product brochure. Review the impurity profile against your product’s known risks. Record whether the supplier’s process and material attributes fit the finished dosage form before you request commercial pricing.

For steroid programs, use our batch-release COA checklist to review a supplier CoA field by field.

3. Review Quality Evidence from the Exact Site

Quality evidence must identify the proposed API and manufacturing site. A corporate certificate or generic laboratory summary does not prove that the batch you buy will come from a suitable source.

Request these documents during the quality review:

• Current GMP evidence for the proposed manufacturing site
• Three recent batch-specific CoAs for the proposed API
• Analytical methods and impurity-profile information
• Stability or retest-date support
• Deviation, OOS, CAPA, and complaint escalation procedures
• Change-control procedure and customer-notification terms
• Audit materials for the site and relevant production area

ICH Q7 says that each API batch should have an authentic CoA on request. The CoA should identify the API, grade where relevant, batch number, release date, and expiry or retest date. See the ICH Q7 CoA requirements

A CoA is supporting evidence, not your finished-product manufacturer’s final release decision. 21 CFR 211.84 requires at least one identity test for each component shipment. It also requires the drug manufacturer to establish the reliability of supplier analyses when accepting a supplier report of analysis.

Review the three CoAs side by side. Look for the same API form, specification version, test methods, batch numbering, retest approach, and impurity reporting. A changing method, unexplained result format, or missing original manufacturer information belongs in the supplier’s follow-up file.

4. Map the US Regulatory and Import Path

US regulatory readiness is a set of records for a specific API, site, and program. It is not a badge that applies to every molecule in a supplier’s catalog.

A Drug Master File, or DMF, is confidential information submitted to FDA about facilities, processes, or articles used to make human drugs. FDA states that DMFs are not required by statute or regulation, and that FDA neither approves nor disapproves them. FDA reviews a DMF when an IND, NDA, ANDA, or BLA references it. FDA’s DMF guidance

Use a DMF Correctly

When your program relies on a Type II API DMF, ask for the holder’s name, DMF number, exact API, and manufacturing-site coverage. Ask whether the holder will issue a Letter of Authorization, or LOA, for your specific application.

The LOA gives FDA permission to review the confidential DMF information in support of the referenced application. A DMF number alone does not establish that the proposed site, process, and material are ready for your program.

Check the Import Records

For an API imported into the United States, FDA says foreign establishments that manufacture, repack, relabel, or salvage the API must register with FDA. FDA also says foreign firms must list commercially distributed APIs and identify known importers. FDA’s API import requirements

Match the registration, listing, US agent, importer, manufacturer, and consignee to the legal entities in the shipment plan. FDA uses those records when evaluating import entries.

Registration and listing still do not mean FDA approved the API or finished drug product. FDA’s registration system explains that registration and listing do not indicate approval or FDA verification of the submitted information.

5. Compare Quotes on the Same Basis

A quote is comparable only when every supplier prices the same material from the same site under the same delivery terms. Normalize the request before you compare unit prices.

Put the following details in every RFQ:

• Exact API name, form, grade, and specification version
• Named manufacturing site and proposed batch range
• Required quantity and delivery schedule
• Sample, qualification, and commercial quantities
• Incoterm and destination
• Required storage and shipping conditions
• Required documents and release timing
• Payment terms and change-notification obligations

Then compare the landed commercial decision, not the quoted kilogram price. Include freight, insurance, import handling, testing, release timing, sample work, and the cost of holding safety stock.

A quality agreement should name responsibilities for specifications, supplier qualification, sampling, testing, deviations, change control, complaints, and recalls. FDA quality-agreement guidance recommends assigning those component-management responsibilities clearly between the parties.

The lowest quote wins only when the supplier also meets the technical, quality, regulatory, and continuity requirements in the scorecard.

6. Approve the Supplier and Keep Monitoring

Supplier approval is a sequence, not a one-time document exchange. Complete the document screen first, then technical review, quality review, regulatory review, quality agreement, sample or qualification batch, and commercial approval.

Record the final decision in one file. That file should show the proposed API, site, scorecard, reviewed documents, open actions, approval scope, and requalification trigger.

Treat these changes as requalification events:

• New manufacturing site
• New synthetic route or critical raw-material source
• Changed specification or analytical method
• Changed packaging, storage, or transport conditions
• Changed distributor, repacker, or importer
• Significant deviation, recall, or quality-system issue

ICH Q7 calls for formal change control for changes to raw materials, specifications, analytical methods, facilities, processing, packaging, and labelling. It also expects API distribution systems to support batch traceability for recalls. ICH Q7 change control

For US buyers sourcing a broader portfolio, our US pharmaceutical raw-material catalog can help begin molecule discussions. Use the scorecard before treating any catalog item as an approved source.

FAQs

Can a Distributor Issue the Letter of Authorization?

The DMF holder must authorize FDA to reference the DMF. A distributor can coordinate the request, but the buyer should identify the actual DMF holder and ensure the LOA covers the intended application, API, and site. FDA’s ANDA DMF guidance includes a valid LOA as part of the DMF support process. FDA DMF guidance

Can a Sample Qualify a Commercial API Source?

No. A sample can show early technical compatibility, but it does not establish commercial batch consistency, capacity, site identity, change control, or regulatory support. Use the sample review as one part of the approval record.

Should a US Program Qualify a Backup API Source?

Yes, when an interruption from the primary source would delay development, filing, or commercial supply. Start the backup review before the primary source becomes unavailable, because the alternate site needs its own technical, quality, and regulatory assessment.

What Changes Require a New Supplier Review?

A new site, process, specification, test method, package, storage condition, or supply-chain handoff requires a new review. Each change can affect API quality, filing consistency, or delivery conditions. Record the change and its impact before accepting new material.

At Aarise Pharma, we manufacture and export steroid, peptide, hormone, and general pharmaceutical APIs from Haridwar, India. Explore our API manufacturing categories or speak with us about documentation, specifications, and samples for your proposed US program.